Listed times are in Central European Time (CET)

WELCOME TO DAY ONE

Rene Bernards & Marisol Soengas

Session 1: Signalling

Chairs: Marco Hofmann & Anna Obenauf

Marco Hofmann Boehringer Ingelheim, Austria

"SOS1i combinations enhance the anti-tumor response and overcome resistance"

Q&A 13:25-13:40

Chiara Ambrogio University of Torino, Italy

“Signaling plasticity in pre-clinical models of adaptive and acquired resistance to KRAS-G12C inhibitors”

Q&A 14:00-14:15

Sara Mainardi Netherlands Cancer Institute, Netherlands

Proffered Paper 1: "From bench to bedside and back to bench: identification of potential resistance markers for the SHERPA (SHP2 and ERK inhibition in pancreatic cancer) trial."

Q&A 14:25-14:30

PROGRAMME BREAK

Frank McCormick UC San Francisco, USA

"Targeting KRAS and its immediate effectors"

Q&A 15:05-15:20

Kevan Shokat UC San Francisco, USA

“Drugging undruggable targets in cancer”

Q&A 15:40-15:55

PROGRAMME BREAK

Session 2: Immune Regulation

Chairs: Marisol Soengas & Ralph Neumueller

Caroline Robert Gustave Roussy, France

"Melanoma Persitent cells : Can we track the invisible?"

Q&A 16:30-16:45

Roger Lo UCLA, USA

'Stabilizing the Genome to Prevent Acquired MAPK Inhibitor Resistance'

Q&A 17:05-17:20

Poster Spotlights

3 top abstracts presented as 3-minute flash talks

End of Day 1 Webinar

Once the Webinar has ended we will take a 15-minute break before we begin our Virtual Poster Discussion Session 1

Virtual Poster Discussion Session 1

An informal and interactive 'virtual' opportunity for participants to browse the posters and make new connections. This 60-minute session will be delivered through the Zoom Meeting platform.

END OF DAY ONE

Listed times are in Central European Time (CET)

Virtual Poster Discussion Session 2

An informal and interactive 'virtual' opportunity for participants to browse the posters and make new connections. This 60-minute session will be delivered through the Zoom Meeting platform.

10-minute transition break (Meeting to Webinar)

WELCOME TO DAY TWO

Session 3: Resistance

Chairs: Marco Hofmann & Ralph Neumuller

Antreas Hindoyan Amgen Inc

“Putative mechanisms of acquired resistance to sotorasib in KRAS p.G12C-mutated NSCLC and CRC: plasma biomarker analysis of CodeBreaK 100”

Q&A 14:35-14:50

Paolo Armando Gagliardi Institute of Cell Biology, Switzerland

Proffered Paper 2: "Targeting apoptosis-induced collective MAPK activity waves to improve breast cancer therapy"

Q&A 15:00-15:05

Fernando Calvo Baltanas University of Seville, Spain

Proffered Paper 3: "Validation of SOS1/2 RASGEFs as therapeutic targets in KRASG12D-driven lung adenocarcinoma"

Q&A 15:15-15:20

PROGRAMME BREAK

Anna Obenauf Research Institute of Molecular Pathology, Austria

"Towards rational combination therapies: Understanding tumor evolution during therapy response and resistance"

Q&A 15:55-16:10

Rene Bernards The Netherlands Cancer Institute, Netherlands

"Paradoxical activation of oncogenic signaling as a cancer treatment strategy"

Q&A 16:30-16:45

Julian Downward Francis Crick Institute, UK

"KRAS oncogene signalling and the tumour immune microenvironment in lung cancer"

Q&A 17:05-17:20

SUMMARY AND END OF DAY TWO

Rene Bernards & Anna Obenauf